WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H123053
CAS#: 2243882-74-6
Description: WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
Hodoodo Cat#: H123053
Name: Wee1-IN-5
CAS#: 2243882-74-6
Chemical Formula: C26H28Cl2N6O
Exact Mass: 510.17
Molecular Weight: 511.450
Elemental Analysis: C, 61.06; H, 5.52; Cl, 13.86; N, 16.43; O, 3.13
Synonym: Wee1-IN-5; Debio 0123; 2243882-74-6; SCHEMBL23298351; EX-A5145; HY-147054;
IUPAC/Chemical Name: 3-(2,6-dichlorophenyl)-1-methyl-7-((3-methyl-4-(1-methylpiperidin-4-yl)phenyl)amino)-2,3-dihydropyrimido[4,5-d]pyrimidin-4(1H)-one
InChi Key: VWHNEYAANMETIA-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H28Cl2N6O/c1-16-13-18(7-8-19(16)17-9-11-32(2)12-10-17)30-26-29-14-20-24(31-26)33(3)15-34(25(20)35)23-21(27)5-4-6-22(23)28/h4-8,13-14,17H,9-12,15H2,1-3H3,(H,29,30,31)
SMILES Code: CC1=C(C=CC(=C1)NC2=NC=C3C(=N2)N(CN(C3=O)C4=C(C=CC=C4Cl)Cl)C)C5CCN(CC5)C
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 511.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends
Pharmacol Sci. 2016 Oct;37(10):872-881. doi: 10.1016/j.tips.2016.06.006. Epub
2016 Jul 14. PMID: 27427153.
2: Kong A, Mehanna H. WEE1 Inhibitor: Clinical Development. Curr Oncol Rep. 2021
Jul 16;23(9):107. doi: 10.1007/s11912-021-01098-8. PMID: 34269904; PMCID:
PMC8285350.
3: Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, Simonetti G. A WEE1
family business: regulation of mitosis, cancer progression, and therapeutic
target. J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2.
PMID: 32958072; PMCID: PMC7507691.
4: Koh SB. The expanding role of WEE1. Cell Signal. 2022 Jun;94:110310. doi:
10.1016/j.cellsig.2022.110310. Epub 2022 Mar 16. PMID: 35304285.
5: Shi L, Xue X, Tian H, Ye H, Wang H, Wang R, Liu Y, Zhang C, Chen Q, Sun L.
WEE1 promotes endometriosis via the Wnt/β-catenin signaling pathway. Reprod Biol
Endocrinol. 2021 Oct 22;19(1):161. doi: 10.1186/s12958-021-00844-8. PMID:
34686198; PMCID: PMC8532311.